Authors


Alexandra Ward

Latest:

China Confirms Case of Bubonic Plague

Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.


Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Latest:

Twice-Yearly Lenacapavir May Change the World— If We Make It Work

Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.


Gail Connor Roche

Latest:

Lower Respiratory Infections Linked with Influenza Lead to Substantial Global Health Loss

In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.


Courtney Moc, PharmD, MS

Latest:

Current and Potential Treatment Options for Stenotrophomonas maltophilia Infections

We review current and emerging treatment options for infections caused by the difficult-to-treat, intrinsically multidrug-resistant organism Stenotrophomonas maltophilia.


Amesh A. Adalja, MD

Latest:

COVID-19: A Primer

This virus has multiple facets and highlights a need for real-time learning.



Rhonda E. Colombo, MD, MHS

Latest:

Examining An Emergence of Multi-drug Resistance Among Candida Species

Despite having emerged as either the third or fourth leading cause of blood stream infections in the United States, the threat of multi-drug resistant Candida species remains an underappreciated concern.


Adriano de Bernardi Schneider, MSc

Latest:

What Can We Learn From Outbreaks of HIV and Zika?

Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.


Jason M. Pogue, PharmD

Latest:

Sulbactam for Treatment of Carbapenem-Resistant Acinetobacter baumannii

This is a challenging pathogen, requiring pharmacokinetic and pharmacodynamic considerations; the recent FDA approval of sulbactam-durlobactam offers new hope.



HCPLive staff

Latest:

Survey Finds US Hospitals Falling Short on Preventing C. Difficile Infection

A survey of 571 US hospitals regarding practices used to prevent Clostridium difficile infection indicates that nearly half of the facilities appear to not be taking steps to prevent the infection that kills nearly 30,000 people and sickens hundreds of thousands more each year, despite strong evidence that these steps work.


MAJDI AL-HASAN, MBBS

Latest:

Get Off the SOFA! Introducing the Quick Pitt Bacteremia Score

The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.


Nabil Zeineddine, MD

Latest:

A Case of CNS Nocardia farcinica Presenting as Aphasia in an Immunocompetent Host

Quick recognition is key to early initiation of treatment and long-term survival.


Dagan Coppock, MD

Latest:

Mixed Fungal Brain Abscess

Clinicians review a patient case including diagnosis, treatment, and follow-up.


Kenny Walter

Latest:

Continuous Vancomycin Infusions Vs Intermittent Infusions Shows No Benefit

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.


LYNN NGUYEN, PHARMD

Latest:

Multidrug-Resistant Pseudomonas aeruginosa Infections: Hard to Treat, But Hope on the Horizon?

Two recently approved agents offer significant activity against these hard-to-treat conditions.


ANN MARIE PORRECA, PHARMD, BCPS

Latest:

Treatment Options to Address the Threat of Carbapenem-Resistant Enterobacteriaceae

New agents are in development, but none represent a magic bullet for the problems that CRE infections present.


Alexandra Ward, MA

Latest:

ERADICATE: Ceftobiprole Noninferior to Daptomycin for Complicated Staphylococcus aureus Bacteremia

The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.


KATHERINE GRUENBERG, PHARMD

Latest:

Multidrug-Resistant Pseudomonas aeruginosa Infections: Hard to Treat, But Hope on the Horizon?

Two recently approved agents offer significant activity against these hard-to-treat conditions.


Paul Sax, MD

Latest:

Teaching Old Dogs New Tricks: Make the Most of Twitter to Boost ID Education, Engagement, and Advocacy

Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.


Warren Rose, PharmD

Latest:

Synergy Between Antibiotics and The Innate Immune System

Growing evidence suggests that antimicrobials also interact with host innate immunity to provide potent indirect effects which enhance bacterial clearance and may result in more rapid and complete effects


Kristie Zappas, PharmD, BCPS-AQ ID

Latest:

De-Escalation in Under 48 Hours Reduces 90-Day C difficile Infection Incidence 3-Fold

A novel study from Seddon and colleagues adds to the body of evidence that supports what antimicrobial stewardship programs are so often challenged to do, early de-escalation.


Jamie L. Wagner, PharmD

Latest:

Using IL-6 Inhibitors to Treat COVID-19

Use of an IL-6 inhibitor has the potential to prevent the cytokine storm caused by severe COVID-19 infection.


Sarah Melvin

Latest:

Inappropriate Antimicrobial Use in the Emergency Department for Skin and Soft Tissue Infections

Studies have shown high rates of inappropriate antibiotic prescribing and opportunity for improvement when it comes to ABSSSIs.


José Mauro Peralta, PhD

Latest:

A True Case Definition of Zika Virus Infection Should Still Be Pursued in Arbovirus Co-Transmission Areas

Differences in the clinical presentations of ZIKV infection which are occurring in different parts of the world might be an obstacle to setting a case definition that is good for use in all areas.


JENNIFER BAILEY, PHARMD

Latest:

New Initiatives for HIV Taking Off This Year

Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.


RAZIEH KEBRIAEI, PHD+

Latest:

Bacteriophage-Antibiotic Combinations: A Promising Alternative for Refractory Infections?

Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.


MICHAEL J. RYBAK, PHARMD, MPH, PHD+*

Latest:

Bacteriophage-Antibiotic Combinations: A Promising Alternative for Refractory Infections?

Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.


Liza Vaezi, PharmD, MSc, BCPS-AQID

Latest:

Early Adjunctive Corticosteroids Do Not Improve Outcomes in HIV-Negative Adults With PcP

The clinical characteristics and outcomes of Pneumocystis jirovecii pneumonia differ in immunocompromised patients with and without HIV.


Lisa Astor

Latest:

Herpes Zoster Vaccine Subunit Prevents Herpes Zoster Episodes Following HSCT

The vaccine reduced the risk of herpes zoster by 68.2% in high-risk recipients of hematopoietic stem cell transplant.

© 2024 MJH Life Sciences

All rights reserved.